# Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)

> **NCT02185820** · PHASE1,PHASE2 · COMPLETED · sponsor: **European Myeloma Network B.V.** · enrollment: 57 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02185820
- **Lead sponsor:** European Myeloma Network B.V.
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2015-07
- **Final completion:** 2023-01
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2023-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02185820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02185820, "Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02185820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*